R. Paul Robertson, M.D. is an Emeritus Professor of Medicine at the University of Washington and at the University of Minnesota. Dr. Robertson has published 395 peer-reviewed manuscripts with primary emphasis on pancreatic islet function in humans, animals, and clonal cell lines. His early studies were the first to demonstrate defects involving the adverse effects of glucose toxicity on the critical insulin promoters Pdx-1 and MafA associated with glucose toxicity. More recent research demonstrated adverse metabolic consequences of using the liver as a transplant site for pancreatic islet transplantation in patients with type 1 diabetes mellitus and in autoislet recipients following pancreatectomy for chronic, painful pancreatitis.
<p><span style="color: rgb(83, 86, 90); font-family: nexussans, arial, sans-serif; font-size: 20px;">R. Paul Robertson, M.D. is an Emeritus Professor of Medicine at the University of Washington and at the University of Minnesota. Dr. Robertson has published 395 peer-reviewed manuscripts with primary emphasis on pancreatic islet function in humans, animals, and clonal cell lines. His early studies were the first to demonstrate defects involving the adverse effects of glucose toxicity on the critical insulin promoters Pdx-1 and MafA associated with glucose toxicity. More recent research demonstrated adverse metabolic consequences of using the liver as a transplant site for pancreatic islet transplantation in patients with type 1 diabetes mellitus and in autoislet recipients following pancreatectomy for chronic, painful pancreatitis.</span><br></p>
